LISA PAPE: Open Payments
NPI 1578072351 · COUNCIL BLUFFS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$701 in 41 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $107 · 2025 $701
Food & beverage: $701
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $182 |
| Astellas Pharma US Inc | 7 | $113 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| E.R. Squibb & Sons, L.L.C. | 4 | $64 |
| Novo Nordisk Inc | 3 | $47 |
| Lundbeck LLC | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
Products named: Veozah, REXULTI, VRAYLAR, QULIPTA, ELIQUIS, CAMZYOS, PURIFIED CORTROPHIN GEL, UBRELVY.
Industry payments across IA — which companies pay providers there.
